Company Snapshot

Investment Thesis

Medtronic develops and manufactures cardiac rhythm devices, structural heart products, surgical tools, and diabetes therapies used by hospitals worldwide.

  • Cardiovascular Leadership: Pacemakers, defibrillators, and transcatheter valves maintain leading share in heart therapies.
  • Surgical Robotics: Hugo robotic-assisted surgery platform expands Medtronic's presence in minimally invasive procedures.
  • Diabetes Ecosystem: Next-gen insulin pumps and continuous glucose monitoring target improved outcomes for Type 1 patients.

MedTech Portfolio

Therapy Areas Cardiovascular, Neuroscience, Medical Surgical, and Diabetes segments
Global R&D 15,000+ scientists and engineers advancing device innovation
Regulatory Pipeline Dozens of PMA and CE approvals targeted over the next three years
Healthcare Partnerships Value-based care programs align device adoption with improved outcomes

Insights from Medtronic FY2024 earnings materials.

Recent Performance

MTD -0.63%
QTD -4.94%
YTD +12.35%
5Y -12.03%

Shares tread water as investors await consistent growth from robotics and diabetes launches despite healthy order pipelines.

Strategic Insights

Shift to Procedures of the Future

Robotics, navigation, and AI are central to Medtronic's mission of transforming surgical care.

Emerging Market Penetration

Localized manufacturing and training expand access to sophisticated therapies worldwide.

Integrated Diabetes Care

Closed-loop pump systems aim to regain share against competing diabetes technologies.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...